Pharming Group N.V.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | — | -0.07 | -7100.00% |
| 2026-03-12 | 0.01 | 0.07 | +460.00% |
| 2025-11-06 | — | 0.01 | +122.22% |
| 2025-07-31 | -0.01 | 0.01 | +148.00% |
| 2025-05-08 | -0.02 | -0.02 | +12.00% |
| 2025-03-13 | 0.01 | 0.01 | -41.18% |
| 2024-10-24 | — | — | +20.00% |
| 2024-08-01 | — | — | +50.00% |
| 2024-05-08 | 0.01 | -0.02 | -371.43% |
| 2024-03-14 | — | — | -188.89% |
| 2023-10-26 | -0.01 | 0.01 | +138.46% |
| 2023-08-03 | -0.02 | — | +111.76% |
| 2023-05-11 | — | -0.02 | — |
| 2023-03-16 | — | -0.02 | — |
| 2022-10-27 | — | 0.01 | — |
| 2022-08-04 | 0.01 | 0.01 | -22.22% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PHAR | -23.50% | -15.65% | -26.49% | +22.55% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -26.47% | -11.01% | -23.04% | +9.86% |